No Picture
News

Epic Sciences Unveils New Liquid Biopsy Test to Predict Sensitivity to PARP Inhibitors in Prostate Cancer Trial

SAN DIEGO, April 3, 2019 /PRNewswire/ — Epic Sciences, Inc. and its research partners today report the use of the company’s new circulating tumor cell (CTC) homologous recombination deficiency (HRD) liquid biopsy assay for the prediction of drug re… […]

No Picture
News

Jean-Baptiste Agnus Joins Ajinomoto Bio-Pharma Services’ Global Leadership Team as Vice President of Sales and Marketing

SAN DIEGO and WETTEREN, Belgium, April 3, 2019 /PRNewswire/ — Ajinomoto Bio-Pharma Services (“Aji Bio-Pharma”), a leading global provider of bio-pharmaceutical contract development and manufacturing services, is pleased to announce that Jean-Bapti… […]

No Picture
News

OncoSec Presents Promising Preclinical Data with New Product Candidate and Improved Electroporation Generator at AACR Annual Meeting

Data Shows New Product Candidate, using both CXCL9 and anti-CD3 with Enhanced IL-12, Drives Strong Immune Response to Shrink TumorsData Shows Improved Electroporation Generator Greatly Enhances DNA-Plasmid-based Anti-tumor Regression in a Difficult to … […]

No Picture
News

Heron Announces European Medicines Agency Validation of Marketing Authorisation Application for HTX-011 for Postoperative Pain Management

SAN DIEGO, April 1, 2019 /PRNewswire/ — Heron Therapeutics, Inc. (Nasdaq: HRTX), a commercial-stage biotechnology company focused on improving the lives of patients by developing best-in-class treatments to address some of the most important unmet… […]

No Picture
News

Biocept Broadens Commercial Focus of its Target Selector Liquid Biopsy Platform to Include Urology Market Segment

Expansion of Biocept’s EmpowerTC(TM) offering now includes predictive and prognostic biomarker testing to aid pathologists and urologists in the management of patients diagnosed with prostate cancer

SAN DIEGO, March 26, 2019 /PRNewswire/ — Biocept, … […]